227 related articles for article (PubMed ID: 30500189)
1. Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
Rogacki MK; Pitta E; Balabon O; Huss S; Lopez-Roman EM; Argyrou A; Blanco-Ruano D; Cacho M; Vande Velde CML; Augustyns K; Ballell L; Barros D; Bates RH; Cunningham F; Van der Veken P
J Med Chem; 2018 Dec; 61(24):11221-11249. PubMed ID: 30500189
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
[TBL] [Abstract][Full Text] [Related]
3. Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.
Whitehurst BC; Young RJ; Burley GA; Cacho M; Torres P; Vela-Gonzalez Del Peral L
Bioorg Med Chem Lett; 2020 Jun; 30(12):127192. PubMed ID: 32312582
[TBL] [Abstract][Full Text] [Related]
4. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
[TBL] [Abstract][Full Text] [Related]
5.
Borthwick JA; Alemparte C; Wall I; Whitehurst BC; Argyrou A; Burley G; de Dios-Anton P; Guijarro L; Monteiro MC; Ortega F; Suckling CJ; Pichel JC; Cacho M; Young RJ
J Med Chem; 2020 Mar; 63(5):2557-2576. PubMed ID: 31922409
[TBL] [Abstract][Full Text] [Related]
6. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
[TBL] [Abstract][Full Text] [Related]
7. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
[TBL] [Abstract][Full Text] [Related]
8. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST
Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of DprE1 inhibitors using AI/CADD approaches.
Chen K; Xu R; Hu X; Li D; Hou T; Kang Y
Drug Discov Today; 2024 Jun; 29(6):103987. PubMed ID: 38670256
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
11. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
[TBL] [Abstract][Full Text] [Related]
12. Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.
Gao C; Peng C; Shi Y; You X; Ran K; Xiong L; Ye TH; Zhang L; Wang N; Zhu Y; Liu K; Zuo W; Yu L; Wei Y
Sci Rep; 2016 Jul; 6():29717. PubMed ID: 27405961
[TBL] [Abstract][Full Text] [Related]
13. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the
Ezquerra-Aznárez JM; Degiacomi G; Gašparovič H; Stelitano G; Sammartino JC; Korduláková J; Governa P; Manetti F; Pasca MR; Chiarelli LR; Ramón-García S
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054958
[TBL] [Abstract][Full Text] [Related]
14. Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
Piton J; Foo CS; Cole ST
Drug Discov Today; 2017 Mar; 22(3):526-533. PubMed ID: 27666194
[TBL] [Abstract][Full Text] [Related]
15. DprE1--from the discovery to the promising tuberculosis drug target.
Mikusová K; Makarov V; Neres J
Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
[TBL] [Abstract][Full Text] [Related]
16. New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.
Pajk S; Živec M; Šink R; Sosič I; Neu M; Chung CW; Martínez-Hoyos M; Pérez-Herrán E; Álvarez-Gómez D; Álvarez-Ruíz E; Mendoza-Losana A; Castro-Pichel J; Barros D; Ballell-Pages L; Young RJ; Convery MA; Encinas L; Gobec S
Eur J Med Chem; 2016 Apr; 112():252-257. PubMed ID: 26900657
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.
Wang P; Batt SM; Wang B; Fu L; Qin R; Lu Y; Li G; Besra GS; Huang H
J Med Chem; 2021 May; 64(9):6241-6261. PubMed ID: 33852302
[TBL] [Abstract][Full Text] [Related]
19. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.
Chikhale R; Menghani S; Babu R; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
Eur J Med Chem; 2015; 96():30-46. PubMed ID: 25874329
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]